Medical innovations

Thanks to our numerous co-operations with companies and partner institutions, you receive access to innovative medical diagnostic and treatment forms.

Cardiovascular diseases, obesity, food intolerances and certain autoimmune disorders are influenced both by genetic factors as well as by diet and lifestyle. Genetic testing gives you valuable insights and tips on prevention.

Shedding light on food intolerances (Nutripass)

The body’s reaction to specific foods depends on your individual genetic predisposition. If you have certain genetic variations, some dietary habits may increase the risk of developing specific illnesses. It is therefore vital to know about your genetic predisposition so you can make the right adjustments to your diet. 

Nutripass von Gene Predictis

You can find further genetic tests in the section "Costs covered by PRIMEO supplementary insurance".

Do oral contraceptives increase the risk of thrombosis? Is there a risk of my unborn child suffering a genetic disorder? How high is the risk of cancer in my family? Take a test to see if you or your family are affected.

Detecting the risk of thrombosis (Pill Protect)

The Pill Protect genetic test determines your risk of suffering from venous thrombosis as a result of taking the contraceptive pill. The test also considers other risk factors in its analysis.

Non-invasive prenatal test to determine genetic disorders (NIPT)

From as early as the ninth week of pregnancy, non-invasive tests, i.e. tests that do not require devices or catheters to be inserted into the body, can determine with a high level of certainty whether an unborn child has a genetic disorder such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) or trisomy 13 (Patau syndrome). 

As of mid-July 2015, this examination (trisomy 21, 18 and 13) has been covered by basic insurance, provided the requirements of the Health Care Benefits Ordinance (KLV) are met. If these requirements are not met, PRIMEO supplementary insurance covers the costs. 

Detecting hereditary forms of cancer (myRisk)

5% to 10% of all cancers are hereditary. Since the mutations can be inherited, cancer cases often occur in clusters in the families affected. A genetic test can offer clarity and confirm the presence of mutations for the most common hereditary cancers. 

MyRisk from Myriad Genetics Pill Protect from Gene Predictis NIPT from LifeCodexx

You can find further genetic tests in the section "Costs covered by PRIMEO supplementary insurance".

A diagnosis of cancer causes uncertainty and worry for those affected. It raises many questions. An appropriate test can offer some clarity and help you choose the right treatment.

Determining the aggressiveness of prostate cancer (Prolaris)

Prolaris is a gene expression test that can help to predict how prostate cancer may progress. The test is carried out on existing tumour tissue (biopsy) and accurately measures the activity of specific genes that directly influence tumour growth. 

Analysis to determine choice of treatment for ovarian cancer (Tumor BRACAnalysis CDx)

Conventional tests exclusively recognise hereditary changes detected in the blood. The Tumor BRACAnalysis, meanwhile, also reveals mutations that only occur in the tumour.

Diagnosing skin cancer (myPath)

Melanoma is a form of skin cancer that can be fatal if not treated early. For this reason, it's important to distinguish between an innocuous mole or birthmark and a malignant melanoma. However, 10% to 15% of tests performed do not provide conclusive results. The myPath Melanoma test can offer greater clarity in these cases.

Myriad Genetics

You can find further genetic tests in the section "Costs covered by PRIMEO supplementary insurance".

Medications can trigger unwanted side effects and in some cases they may even be ineffective. Different medications can also interact with one another if you have to take several at the same time. 

Genetic test assesses the tolerability and efficacy of medication (Cypass)

The effect of any medication is influenced by metabolic processes: how the body converts and eliminates substances. The Cypass genetic test assesses these metabolic processes as well as 16 genes and 97 clinically significant genetic variants that are involved in the breaking down and tolerability of medications in the body.

Cypass Extended – extended genetic test on tolerability of medication

The Cypass Extended genetic test is more comprehensive than the Cypass test. It analyses 25 genes in addition to 127 genetic variants that are involved in the breaking down and tolerability of medications. 

Genetic test to determine tolerability of medication for reducing cholesterol levels (statins)

Statins are the most commonly prescribed medication in Switzerland. They help reduce blood lipid levels, in particular “bad” cholesterol (30–50%), and play a role in reducing the risk of cardiovascular disease. However, the effectiveness of statins is impacted by certain genetic variants that are part of the patient's DNA.

Cypass and Cypass Extended from Gene Predictis Statins from Gene Predictis

You can find further genetic tests in the section "Costs covered by PRIMEO supplementary insurance".

Genetic factors play a key role in some diseases. The enormous progress that has been made in medical genetics research is a key reason why today’s healthcare has improved. 

With PRIMEO supplementary insurance, you benefit from direct access to leading experts in the field of medical genetics in Switzerland: 

  • Prof. Dr. phil. nat. Sabina Gallati
  • Dr. med. dipl. Natw. ETH Roland Spiegel

Do you have semi-private or private insurance? Then you can also benefit from the expert second opinion service. 

When should you seek the advice of a genetic expert?
  • If you have questions about genetic analyses (testing, options, limits, consequences)
  • If you have questions about the existing results of a genetic test
  • For issues related to sample collection and the genetic testing procedure
  • To obtain recommendations for suitable service providers (e.g. laboratories) and/or general practitioners/specialists
Interested?

Contact us on 058 340 13 84 (Monday to Friday, from 8 a.m. to 12 p.m. and from 1 p.m. to 5 p.m.). We will then contact a genetic expert. 

Please note: consultations are offered in English and German.

Innovative examinations

Healthcare is constantly improving thanks to technological progress and digitisation. This enables us to develop even better and more accurate examination methods. Patients with PRIMEO supplementary insurance receive exclusive access to the following innovative examinations:

  • Cardio Explorer (Provider: Exploris AG)
    Blood test to identify life-threatening constrictions (stenosis) in blood vessels.
  • Alleye app (Provider: Oculocare medical AG)
    Test to identify retinal disorders (age-related macular degeneration, diabetic macular oedema).
  • RetinaLyze (Provider: RetinaLyze System GmbH)
    Test to identify diabetic retinopathy, age-related macular degeneration and glaucoma (cataracts).
  • CardioInsight Mapping Vest (Provider: Medtronic AG)
    Test to identify cardiac arrhythmia to produce 3D cardiac maps.
  • derma2go (Provider: derma2go AG)
    Platform for the provision of online advice by the patient’s own dermatologist
  • IBSchek (Laboratory: Unilabs)
    Blood test to identify irritable bowel syndrome (IBS).
Self-test to identify a potential HIV infection 

You can perform a self-test from a pharmacy at home in order to obtain rapid, reliable results. Patients with PRIMEO supplementary insurance receive exclusive paid access to the following innovative quick tests: 

  • autotest VIH (provider: Mepha Schweiz AG)
  • EXACTO HIV test (provider: Biosynex SA)
  • Comparable HIV self-tests from other providers/distributors
Medical products: treatment of chronic bladder infections by a urologist

Medical technology products or medical aids are used to detect and treat illnesses. Patients with PRIMEO supplementary insurance receive exclusive paid access to the following medical products:

Interested?

Contact us on 058 340 13 84 (Monday to Friday, from 8 a.m. to 12 p.m. and from 1 p.m. to 5 p.m.). We will review your request and notify you of the costs covered.

Further information

If you have taken out PRIMEO supplementary insurance, Helsana will cover 90% of the costs up to a total of CHF 5,000 per calendar year for innovative diagnostic and treatment forms. Helsana will be invoiced directly for your test. 

Patients with PRIMEO supplementary insurance receive exclusive paid access to other genetic tests:

Food intolerance
  • BMT food inflammation test (provider: Biomarkers Test/Desintrade ltd)
    Test to measure the level of inflammation in the body and the personal food profile. 
  • Lactose intolerance, genotype (laboratory: Viollier and others)
    Test to detect genetic predisposition to lactose intolerance.
Individual risk assessment for a potential illness
  • Colox (provider: Novigenix and service providers/laboratories such as Gene Predictis and others) 
    Non-invasive blood test for the early detection of colorectal cancer.
  • Additional genetic tests produced by Gene Predictis by request
  • Additional genetic tests produced by Sophia Genetics SA by request
Targeted cancer treatments
  • Solid Tumor Solution (provider: Sophia Genetics SA)
    Molecular diagnostic application to support experts in the detection and characterisation of genomic variants.
  • Genetic tests produced by Caris Life Sciences
    Molecular tests to diagnose and treat cancer (tumour profiling).
  • Genetic tests produced by NEO New Oncology GmbH 
    Oncological tests for the analysis of tissue and blood (liquid biopsy) in solid tumours.
Determining the tolerability of medicines
Interested?

Contact us on 058 340 13 84 (Monday to Friday, from 8 a.m. to 12 p.m. and from 1 p.m. to 5 p.m.). We will review your request and notify you of the costs covered.

More about PRIMEO

These laboratory tests are not covered by basic insurance. For policyholders without PRIMEO supplementary insurance, Helsana has agreed the following special conditions for the tests listed above:

  • Myriad Genetics: 15% discount on the official recommended list price of Prolaris, Brac and Mypath and a 20% discount on the official recommended list price of MyRisk
  • Gene Predictis: 20% discount on the official list price of Cypass, Cypass Extended and statins

Helsana Group policyholders benefit from generous discounts on other medical innovations:

  • Gene Predictis: 10% discount
  • Myriad: 15% discount

If you are interested in an innovative treatment form, please consult your doctor. Most tests are only carried out if prescribed by a doctor. The partner firms make the results directly available to the doctor.

Do you have questions?

We're here to help.